Effects of sulfinpyrazone on early graft closure after myocardial revascularization

Hans R. Baur, Robert A. VanTassel, Claus A. Pierach, Fredarick L. Gobel

Research output: Contribution to journalArticlepeer-review

50 Scopus citations


The effect of sulfinpyrazone on the incidence of early postoperative closure of saphenous vein bypass grafts was compared with placebo in a prospective randomized study of 255 eligible patients. Treatment with sulfinpyrazone (800 mg/day) was started 24 hours after operation in 130 patients; 125 patients received placebo. Graft blood flow was measured at operation in 96 percent of all patients. Graft angiography was performed between the 7th and 14th postoperative days. There was no significant difference between the two groups in graft blood flow, number and diameter of the grafted arteries, left ventricular filling pressure or ejection fraction. During the study 73 patients (41 on sulfinpyrazone, 32 on placebo therapy) were excluded because graft angiography was contraindicated or because of concomitant use of anticoagulant or antiplatelet drugs. The incidence rate of early graft closure in the remaining 182 patients (431 grafts) was 3.8 percent (8 of 212) in the sulfinpyrazone group and 9.1 percent (20 of 219) in the placebo group (p < 0.025). The incidence of graft closure for the sulfinpyrazone and placebo groups classified according to the recipient coronary arteries was: (1) left anterior descending artery: 3 of 98 versus 11 of 111; p < 0.05; (2) left circumflex coronary artery: 3 of 50 versus 5 of 43; difference not significant; (3) right coronary artery: 2 of 64 versus 4 of 65; difference not significant. The incidence of closure in grafts with a flow of less than 30 ml/min did not differ significantly in the sulfinpyrazone and placebo groups (4 of 26 versus 6 of 22). These results suggest that sulfinpyrazone reduces the incidence of early graft closure in grafts with a flow rate greater than 30 ml/min.

Original languageEnglish (US)
Pages (from-to)420-424
Number of pages5
JournalThe American Journal of Cardiology
Issue number2
StatePublished - Feb 1 1982

Bibliographical note

Funding Information:
From the Cardiovascular Section, Department of Medicine, Abbott-Northwestern Hospital and University of Minnesota, Minneapolis, Minnesota. Dr. Baur is a recipient of a grant from the Swiss National Foundation of Research, Bern, Switzerland. Manuscript received March 19, 1981; revised manuscript received July 27, 1981, accepted July 30, 1981. l Present address: Division of Cardiology, Department of Medicine, University Hospital, Bern, Switzerland.


Dive into the research topics of 'Effects of sulfinpyrazone on early graft closure after myocardial revascularization'. Together they form a unique fingerprint.

Cite this